Executive Director
AstraZeneca
Bret Sellman, PhD is Executive Director and Head of Bacteriology and Vaccines in Early Vaccines and Immune Therapies at AstraZeneca. He has over 20 yrs of industry experience in antibacterial vaccine and monoclonal antibody research and development. He has worked at MedImmune / AstraZeneca for >15 years where he has led antibacterial monoclonal antibody programs from discovery thru Phase 2 clinical testing and has recently started building an antibacterial research team at AstraZeneca. Prior to MedImmune, he worked at Wyeth Vaccine Research in bacterial vaccine discovery. He earned his B.S. in microbiology from New Mexico State University and his PhD in microbiology and immunology from the University of Oklahoma Health Sciences Center before completing his post-doctoral training at Harvard Medical School studying bacterial toxin biochemistry